Primary bloodstream infection as an indication: Regulatory perspective FDA/IDSA/ISAP Workshop April 15, 2004 David Ross, M.D., Ph.D.

Slides:



Advertisements
Similar presentations
University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
Advertisements

Role of MRSA Swabs for De-escalation of Antibiotics in HCAP
H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.
Correlation of Leukocyte Count with Clinical Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: Results from Rapid Empiric Treatment.
Blood Culture. Bacteremia: Types  Transient: Disruption of mucosal surfaces (dental or surgical procedures)  Intermittent: Associated with abscesses.
Chapter 15 Newborn (Perinatal) Guidelines ( )
Microbiologic Surrogates: An Industry Perspective Barry Eisenstein, MD Senior Vice President, Research and Development Cubist Pharmaceuticals Clinical.
Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 Sheldon L. Kaplan, MD Baylor College of Medicine Texas.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
1 Catheter-Related Bloodstream Infection Guidance Revisited Janice Pohlman, M.D. FDA AIDAC Presentation October 14, 2004.
C-1 Staphylococcus aureus Bacteremia and Endocarditis: A Bad Bug and A New Drug G. Ralph Corey M.D. Professor of Internal Medicine and Infectious Diseases.
Use of antibiotics. Antibiotic use Antimicrobials are the 2 nd most common drugs prescribed by office based physicians In USA1992: 110 million oral antimicrobial.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.
Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media
Certain Infectious and Parasitic Diseases (A00-B99)
Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.
Julio A. Ramirez, MD, FACP Professor of Medicine Chief, Infectious Diseases University of Louisville Chief, Infectious Diseases Veterans Affairs Medical.
Sarah Struthers, MD March 19, 2015
Perinatal CDC Prevention Guidelines Priscilla Joe, MD.
Antibiotics Tamar Barlam Infectious Disease Director, Antimicrobial Stewardship.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
سورة البقرة ( ۳۲ ). Influenza is a serious respiratory illness which can be debilitating and causes complications that lead to hospitalization and.
Expected Mortality CHF, COPD & Afib –WOB, Sats, RR –BiPAP –ABG results –Thin, sunken temples –BP, gtt’s started Expected Mortality Rate: 1.7% CHF, COPD.
Bacteremia and CRBSI as Labeled BSI Indications: A Regulatory History Alfred Sorbello, DO Medical Officer CDER/Division of Anti-Infective Drug Products.
Clinical Trials Considerations in Primary Bacteremia due to Staphylococcus aureus Clinical Trials Considerations in Primary Bacteremia due to Staphylococcus.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
Life-Threatening Infections: Diagnosis and Antimicrobial Therapy Selection.
Rule Out UTI. Shaikh N et al. Prevalence of urinary tract infections in childhood. A meta- analysis. Ped Infect Dis J 2008.
Implications for clinical trials for diabetic foot infections (DFI) Anti-Infective Drugs Advisory Committee October 28, 2003 David Ross, M.D., Ph.D. Division.
1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,
Clinical Trials for Bloodstream Infection / Infective Endocarditis G. Ralph Corey, MD Vance Fowler, MD Duke Clinical Research Institute April 15, 2004.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
1 Observations from Past Approvals for Acute Bacterial Sinusitis Janice Pohlman, M.D. AIDAC Meeting, October 29, 2003.
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
Gülden Çelik. Learning Objectives At the end of this lecture, the student should be able to: Define bacteremia, fungemia, and sepsis List the main types.
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
Catheter-Related Blood Stream Infections A Phase 2 Randomized, Controlled Trial of Dalbavancin vs. Vancomycin Tim Henkel, MD, PhD Executive VP and Chief.
Development of Drugs for Resistant Pathogens Francis P. Tally M.D. Cubist Pharmaceuticals, Inc.
Community Acquired Pneumonia (CAP)
Tuberculosis in Children and Young Adults
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.
Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA.
Prevalence of Bacteremia in Low Risk Patients with Sickle Cell Disease and Fever Shashidhar Marneni, MD Fellow(1 st Year) Pediatric Emergency Medicine.
Urinalysis Orders Among Patients Admitted to the Inpatient General Medicine Service Cost Conscious Project Miriam Nojan PGY-2.
Jeanine Spielberger MD 9/23/2013 INTRAPARTUM ANTIBIOTIC PROPHYLAXIS FOR GROUP B STREPTOCOCCAL INFECTION.
< 회기-강동 합동 컨퍼런스> Systemic Inflammatory Response Syndrome criteria in Defining Severe sepsis Kirsi-Maija Kaukonen, M.D., Ph.D., Michael Bailey, Ph.D.,
1 Review of Efficacy Data New Drug Application NDA /S-008 Cubicin® (daptomycin for injection) Alfred Sorbello, DO Medical Officer FDA, CDER Center.
Cellulitis Darren Wilson Antibiotic Pharmacist Royal Bournemouth Hospital.
LSU Journal Club Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia A Systematic Review and Meta-analysis Scott Hebert,
Community-Acquired Pneumonia Richard G. Wunderink, M.D., and Grant W. Waterer, M.B., B.S., Ph.D. N Engl J Med 2014;370: R3 김선혜 /Prof. 박명재 1.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
1 Issues in Conduct of Catheter Related Infection (CRI) Studies Charles Knirsch, MD, MPH FDA Anti-infective Advisory Committee Meeting October 14, 2004.
PROSPECTIVE COHORT STUDY OF ACUTE PYELONEPHRITIS IN ADULTS: SAFETY OF TRIAGE TOWARDS HOME BASED ORAL ANTIMICROBIAL TREATMENT C. VAN NIEUWKOOP A,*, J.W.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Community Acquired Pneumonia. Definitions Community acquired pneumonia (CAP) – Infection of the lung parenchyma in a person who is not hospitalized or.
Treatment options in a mechanically ventilated young patient
Use of antibiotics.
Kaylee Wentworth, PharmD PGY-1 Pharmacy Resident April 2017
This Program Will Discuss
Antibiotic Stewardship
Community Acquired Pneumonia
Endocarditis is an inflammation of the endocardium, the membrane lining the chambers of the heart and covering the cusps of the heart valves. Infective.
Presentation transcript:

Primary bloodstream infection as an indication: Regulatory perspective FDA/IDSA/ISAP Workshop April 15, 2004 David Ross, M.D., Ph.D.

2 Outline Regulatory history Defining anti-infective (AI) indications Primary bloodstream infection as an AI indication

3 Bloodstream infection (BSI): history 10 drugs indicated for bacteremia or septicemia All labeled prior to 1992 Labeling based on variable or unspecified clinical manifestations in different studies Includes bacteremia associated with focal infection and bacteremia of unknown origin Patients pooled from trials of other indications

4 9/93 Anti-Infective Drugs AC meeting Bacteremia did not affect outcome in a large NDA dataset Bacteremia is due to infection at a primary site Bacteremic SIRS patients form a heterogeneous population Unclear if bacteremic SIRS patients were sicker than nonbacteremic patients

5 9/93 AC conclusions Bacteremia less important than site of infection for classifying infections Study of ‘bacteremic sepsis’ as a separate indication not feasible given heterogeneity of patient population Labeling should include bacteremia in the context of site-specific infections, e.g., “pneumonia with associated bacteremia”

6 Reconsidering BSI as an indication Increased incidence of BSI: u with resistant pathogens (e.g., VRE, MRSA) u without identifiable primary source Issues in measuring drug effect in BSI... u Patient heterogeneity u Differences in natural history for different pathogens u Differences in pathogen epidemiology/virulence u Need to define an identifiable clinical syndrome... before considering as an indication

7 Does bacteremia equal destiny? 28 yo female with patchy infiltrate in one lobe. No comorbidities. HR 80, RR 16. SCx → S. pneumoniae BCx → S. pneumoniae. Mortality risk <0.1% 52 yo male with multilobar pneumonia. Chronic renal failure, uncontrolled DM HR 130, RR 35. Intubated. SCx → S. pneumoniae BCx → negative Mortality risk 27%

8 Not all bacteremias are the same A 76 yo nursing home resident was admitted for altered mental status, hypotension, hypo- thermia, obtundation, and neck stiffness. A CXR showed bi- lateral infiltrates. An LP showed 4,218 WBC/μL (89% segs) and glucose of less than 20 mg/dL. Blood and CSF Cx grew MRSA. Despite MICU transfer, therapy with vancomycin and rifampin, and aggressive supportive care, the patient deteriorated and died 11 days after admission. A 67 yo M with chronic renal failure receiving hemodialysis via an arteriovenous graft was admit- ted for fever to 38.0°C; the patient was otherwise well. No murmur was found and the graft was non-tender. The fever resolved and vancomycin was started. BCx grew MRSA. There was no further fever or other sx. A repeat BCx was positive. A transesophageal echocardio- gram was negative, as was a Doppler ultrasound of the graft. The patient received 4 weeks of IV vancomycin and did well. Repeat BCx were negative.

9 Site-based anti-infective (AI) indication “Infection at a specified body site due to a specified, susceptible microorganism”. (Points to Consider, 1992) Accounts for differences in drug efficacy for infections at different sites Allows demonstration of efficacy from adequate and well-controlled studies Allows description of drug effect in labeling

10 Essentials of an AI indication Must be a recognized disease or condition, or an important manifestation of a disease Definable syndrome with specific clinical manifestations, diagnostic criteria, and therapeutic requirements Drug treatment effect demonstrable via adequate and well-controlled trials using clinically relevant endpoints Describable in labeling

11 AI indications vs. non-indications AI indications Urinary tract infection Osteomyelitis Bacterial meningitis Streptococcal pharyngitis Community-acquired pneumonia Prophylaxis against post- operative infection Non-indications Dysuria Elevated ESR Coma  throat culture for GAS Pleuritic chest pain Decrease in skin colonization

12 CAP UTI Bacteremia Meningitis Endocarditis Complicated IABD Osteomyelitis SSTI

13 BSI vs. bacteremia Candidal BSI (candidemia) u Accepted AI indication u Frequently primary BSI (no identifed underlying infection) u Definable clinical syndrome Escherichia coli bacteremia u Not accepted AI indication u Virtually never primary BSI u Variety of potential underlying infections (e.g., GI, GU) u Variety of clinical manifestations

14 BSI vs. (pseudo)bacteremia Peripheral BCx (n = 1408) Catheter BCx (n = 1408) p value True BSI13.7%14.4%0.59 Contamination1.8%3.8%0.001 Indeterminate0.9%1.6%0.09 Negative83.6%80.1%0.02 Everts RJ et al. J Clin Microbiol. 2001; 39:

15 Bacteremia as a surrogate endpoint Chaisson R et al. Ann. Intern. Med. 1994; 121: Clarithromycin dose 500 mg bid1000 mg bid2000 mg bid Bacterial load at 2 weeks (cfu/mL) Mortality at 12 weeks5.7%25.5%28.0%

16 Questions 1.Is there a distinct patient population with primary bacterial BSI that can be identified at the time of randomization into a clinical trial? 2.If yes, how should patients with bacterial BSI who demonstrate evidence of metastatic infection post- randomization be classified with regard to a) whether the BSI was primary or secondary at the time of randomization; b) outcome? 3.What combination of clinical manifestations, diagnostic criteria (including those excluding other primary infections), therapeutic requirements, and clinically relevant endpoints would define primary BSI due to a specified bacterial pathogen as a unique indication in labeling?